Survival and responses in treatment-naïve (TN) and patients with R/R CLL and del17p and/or TP53 mutations (mut) receiving ibrutinib (Ibr) alone or in combination with rituximab (R). (A) PFS and (B) OS of TN patients with CLL and del17p and/or TP53 mutations (n = 27). (C) PFS and OS (D) of TN CLL patients vs patients with R/R CLL and del17p and/or TP53 mutations. (E) Best responses in the TN patients with del17p and/or TP53 mutations. (F) Best responses in further subset analyses based on treatment (ibrutinib monotherapy/Ibr vs ibrutinib plus rituximab/Ibr + R).